Research programme: HIV integrase inhibitors - Critical Outcome Technologies

Drug Profile

Research programme: HIV integrase inhibitors - Critical Outcome Technologies

Latest Information Update: 16 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Outcome Technologies
  • Class Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research HIV infections

Most Recent Events

  • 15 Apr 2015 Early research is ongoing in Canada
  • 15 Apr 2015 Research programme: HIV integrase inhibitors - Critical Outcome Technologies is available for licensing as of 15 April 2015. http://www.criticaloutcome.com
  • 05 Apr 2015 Critical Outcome Technologies has patent protection for HIV integrase inhibitors in USA and has patents pending for these compounds in Canada and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top